Atlas market file · Equity · United States
MAIA Biotechnology, Inc.MAIA
- Last close
- 1.42
- Change
- +1.43%
- 96-bar range
- 1.16 – 1.56
- As of
- 6 Aug 2026
MAIA Biotechnology, Inc. is a pharmaceutical preparations issuer listed as MAIA on AMEX. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
MAIA
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-52.35% over the window).
Source rail: Yahoo Finance chart API (MAIA). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for MAIA. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
MAIA public profile
Pharmaceutical preparations issuer. MAIA Biotechnology, Inc. is connected to current market context, cited company sources and its retained research file.
MAIA Biotechnology, Inc. trades as MAIA on AMEX. MAIA Biotechnology, Inc. (MAIA) has a latest verified close of 1.42, up 1.43%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files MAIA under USA Stocks, Technology Stocks and Science & Biotech Stocks for browsing.
What changed for MAIA Biotechnology, Inc. today
MAIA Biotechnology Inc. ended the first quarter of 2026 with zero cash in the bank, according to its latest 10-Q filing. The company reported a net loss of $6.4 million for the period ending March 31, 2026, and burned $5.3 million in operating cash flow. With $35.3 million in total assets but $7.6 million in liabilities, the balance sheet is a study in contrasts: plenty of equity on paper, but no liquid funds to pay the rent.
MAIA is a clinical-stage biotechnology company focused on developing cancer therapies, specifically its lead candidate for non-small cell lung cancer. The company has no approved products and no revenue, relying entirely on capital markets and private placements to fund operations. The March 2026 underwriting agreement with Konik Capital Partners LLC raised $120,000, a sum that barely covers a week of operating expenses.
The May 14, 2026 8-K filing reveals that MAIA suspended its at-the-market offering program, effectively cutting off its primary source of cash. The company's research and development spending for the quarter was just $43,651, a figure that suggests the pipeline is either very early stage or very stalled. With 45.2 million diluted shares outstanding and a loss per share of $0.14, the dilution story is already written.
The SEC EDGAR filing index shows a company that files regularly but has little to show in terms of commercial progress. The insider Form 4 filings from July 2, 2026, indicate ongoing governance activity, but the substance behind the filings is thin. The company's market mechanism is entirely dependent on its ability to raise capital, and that tap has been turned off.
What changed in the second quarter is the suspension of the ATM facility, which was the company's only visible source of liquidity. What remains unproven is whether MAIA can secure alternative financing or a partnership deal before its cash position becomes critical. The evidence suggests a company in a holding pattern, with a promising science story but a financial reality that demands urgent attention.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
MAIA technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on MAIA
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep MAIA research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
MAIA FAQ
What is MAIA Biotechnology, Inc. (MAIA)?MAIA Biotechnology, Inc. (MAIA) has a latest verified close of 1.42, up 1.43%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed...
MAIA Biotechnology, Inc. (MAIA) has a latest verified close of 1.42, up 1.43%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for MAIA?MAIA Biotechnology, Inc. (MAIA) has a latest verified close of 1.42, up 1.43%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources,...
MAIA Biotechnology, Inc. (MAIA) has a latest verified close of 1.42, up 1.43%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files MAIA under USA Stocks, Technology Stocks and Science & Biotech Stocks for browsing.
How often is the MAIA page updated?The MAIA public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The MAIA public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for MAIA?The MAIA file starts with SEC EDGAR filings, Nasdaq Trader and TradingView AMEX:MAIA. SEC EDGAR provides the filing anchor for this issuer. The page separates verified...
The MAIA file starts with SEC EDGAR filings, Nasdaq Trader and TradingView AMEX:MAIA. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on MAIA?Yes. The workstation can open MAIA, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open MAIA, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this MAIA page investment advice?No. The MAIA page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The MAIA page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-07-30. Browse FreedomCore Atlas research notes →